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Objective: Subarachnoid hemorrhage and surgical obliteration of ruptured intracranial aneurysms are frequently associated with
neurological and neuropsychological abnormalities. We reported that intraoperative cooling did not improve neurological out-
come in good-grade surgical subarachnoid hemorrhage patients, as assessed by the Glasgow Outcome Scale score or other
neurological and functional measures (National Institutes of Health Stroke Scale, Rankin Disability Scale, Barthel Activities of
Daily Living). We now report the results of neuropsychological testing in these patients.
Methods: A total of 1,001 patients who bled 14 days before surgery were randomly assigned to intraoperative hypothermia
(t  33°C) or normothermia (37°C). Outcome was assessed approximately 3 months after surgery. Patients underwent the
Benton Visual Retention, Controlled Oral Word Association, Rey–Osterrieth Complex Figure, Grooved Pegboard, and the Trail
Making tests. T-scores for each test were calculated from normative data. T-scores were averaged to calculate a Composite Score.
A test result (or the Composite Score) was considered “impaired” if the T-score was two or more standard deviations below the
norm. A Mini-Mental State Examination was also performed.
Results: Neurological outcome data were available in 1,000 patients. Sixty-one patients died. Of the 939 survivors, 873 com-
pleted 3 or more tests (exclusive of the Mini-Mental State Examination). Patients with poor neurological outcomes were less
likely to complete testing; only 3.9% of Good Outcome (Glasgow Outcome Scale score  1) patients were untested, compared
with 38.6% of patients with Glasgow Outcome Scale scores of 3 and 4. There were no prerandomization demographic differ-
ences between the two treatment groups. For hypothermic patients, 16.8% were impaired from their Composite Score versus
20.0% of patients in the normothermic group (p  0.317). For patients in the hypothermic group, 54.5% were impaired on
at least one test, compared with 55.5% of patients in the normothermic group (p  0.865). Similar results were seen in patients
with baseline WFNS scores  I. Mini-Mental State Examination scores in the hypothermic and normothermic groups were
27.4  3.8 and 26.8  4.5, respectively.
Interpretation: This is the largest prospective evaluation of neuropsychological function after subarachnoid hemorrhage to date.
Testing was completed in a high fraction of patients, demonstrating the feasibility of such testing in a large trial. However, the
frequent inability to complete testing in poor-outcome patients suggests that testing may be best used to refine outcome assess-
ments in good-grade patients. Many patients showed impairment on at least one test, with global impairment present in 17 to
20% of patients (18–21% of survivors). This was true even among the patients with the best preoperative condition (WFNS 
1). There was no difference in the incidence of impairment between hypothermic and normothermic groups.
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Subarachnoid hemorrhage (SAH) is associated with a
high mortality rate and a high incidence of neurologi-
cal1–4 and neuropsychological deficits among survi-
vors.5–7 Many methods have been tried to reduce the
frequency of these deficits, particularly in patients re-
quiring surgical clipping of their aneurysms.8–12
We recently completed a large clinical trial examin-
ing the impact of mild intraoperative hypothermia in
patients undergoing surgical therapy to treat (clip) an
acutely ruptured intracranial aneurysm.13 At 3 months
after surgery, we were unable to detect any treatment
benefit as assessed by the Glasgow Outcome Scale
(GOS) score (our primary outcome variable) or by
other neurological measures including the Rankin Dis-
ability Scale, the National Institutes of Health Stroke
Scale (NIHSS), or the Barthel Activities of Daily Liv-
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ing (ADL) Index. More than 60% of patients in both
hypothermic and normothermic groups had “Good
Outcomes” (GOS score  1). Although the trial was
large enough to detect a 10% absolute difference in the
incidence of “Good Outcomes” (eg, 70 vs 60%), we
were concerned from the onset that the GOS,14 al-
though well validated and widely used in studies of
SAH,3,4,15 might not be sufficiently sensitive.
Neuropsychological evaluations have long been used
to aid in the clinical assessment of patients with neu-
rological disease. There is also increasing evidence of
the utility of neuropsychological tests for evaluating
treatment effects in neurologically focused clinical tri-
als. These include pharmacological interventions for
neurodegenerative diseases and epilepsy, and chemo-
therapy and radiotherapy protocols for central nervous
system cancer.16–19 Moreover, several previous studies
have shown that a high fraction of even “Good Out-
come” SAH patients may have neuropsychological ab-
normalities.5,7,20–25 Based on these considerations, we
supplemented our primary and secondary outcome
measures with a battery of neuropsychological tests.
We now report the results of those measures.
Subjects and Methods
The Intraoperative Hypothermia for Aneurysm Surgery Trial
(IHAST) was a large, multicenter, prospective, randomized,
partially blinded clinical trial designed to determine the im-
pact of intraoperative hypothermia (target t  33°C vs t 
37°C) on neurological outcome in 1,000 patients undergoing
surgical aneurysm clipping within 14 days after an acute an-
eurysmal SAH.
Details on trial design, patient eligibility, and study con-
duct have been published previously.13 In brief, nonpregnant
adults with a World Federation of Neurologic Surgeons26
score of I, II, or III, a body mass index of less than 35kg/m2,
and no cold-related disorders were eligible. Patients could
not be endotracheally intubated at the time of preoperative
assessment. Informed consent was obtained either from the
patient or their legal representatives. A permuted block ran-
domization scheme was used, stratified by center and time
between SAH and surgery (0–7 days; 8–14 days). No more
than 2 hours before the planned start of surgery patients
were evaluated and enrolled via a telephone-accessed com-
puter system, which directed the anesthesiologist to use a
numbered opaque envelope containing the patient’s treat-
ment assignment. The envelope was opened only after the
induction of anesthesia. If, before induction, eligibility crite-
ria were no longer met (eg, neurological deterioration), the
envelope was not opened and the patient was not considered
randomized. All study personnel, except the anesthesiologists
involved in intraoperative care, were blinded to treatment as-
signment.
After endotracheal intubation and positioning, a retrocar-
diac esophageal temperature probe (Mon-a-therm Esophageal
Stethoscope XL; Tyco Mallinckrodt, Pleasanton, CA) was in-
serted and patients were covered with a forced-air blanket
connected to a PolarAir heating/cooling unit (Arizant, Eden
Prairie, MN). The use of a circulating water mattress and/or
intravenous cold saline as cooling aids was optional. In pa-
tients randomized to hypothermia, esophageal temperature
was reduced as quickly as possible, without any delay in the
progress of surgery. The goal was to achieve a temperature
between 32.5 and 33.5°C at the time the clip was applied to
the first aneurysm. Temperature in patients randomized to
normothermia was kept between 36 and 37°C. Rewarming
of hypothermic patients began after the last aneurysm had
been secured, and continued until normothermia was
achieved.
After surgery, patients were extubated at the discretion of
the care team. No attempt was made to control postoperative
care, but all aspects of treatment were monitored for either
14 days or until discharge (if this occurred before 14 days).
Patients were also assessed on the day of discharge.
Patients were contacted by telephone or seen in person 3,
6, and 9 weeks after surgery. A final follow-up examination
was conducted approximately 3 months after surgery. At this
time, an extensive battery of tests was completed including:
(1) modified GOS (this was the primary outcome measure
for the trial),14,27 (2) Rankin Disability Scale,28 (3) Barthel
ADL Index,29 (4) NIHSS,30 and (5) a neuropsychology bat-
tery (see later). All evaluations were performed by trained
examiners certified by the University of Iowa Steering Com-
mittee.
Selection of Neuropsychological Tests
The purpose of the neuropsychological evaluation was to
provide a standardized, quantitative assessment of perfor-
mance in key domains of cognition, including memory, lan-
guage, visuomotor and visuospatial abilities, and attention.
The primary criterion in selecting the tests for the battery
was that they be sensitive to cognitive deficits in patients
with circumscribed lesions or more global cerebral dysfunc-
tion. Secondary criteria included that the battery be brief,
relatively free of cultural biases, and amenable to administra-
tion in several languages. The tests chosen for our study were
selected based on analysis of data from the Patient Registry
of the Division of Cognitive Neuroscience, in the Depart-
ment of Neurology at the University of Iowa. This database
includes comprehensive neuropsychological testing and neu-
roimaging on more than 2,000 patients with focal brain le-
sions caused by vascular events or neurosurgical procedures.
In selecting the IHAST test battery, we analyzed data from
94 patients (not included in IHAST) with SAH who had
undergone comprehensive neuropsychological evaluations
(generally including 15–30 individual tests). Each patient
was classified by the evaluating neuropsychologist as cogni-
tively impaired or not impaired. Each individual test score
was coded as impaired or normal based on the criterion of
two standard deviations (SDs) below the mean of the nor-
mative data. We then examined the sensitivity of various
combinations of tests that met the above criteria. A battery
of five tests that showed 95% agreement with the conclusion
of the comprehensive neuropsychological evaluation was
identified. The resulting battery included the Benton Visual
Retention Test,31 Controlled Oral Word Association
(COWA),32 Rey–Osterrieth Complex Figure–Copy,33
Grooved Pegboard (GPB), and Trail Making Test.33,34 In
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addition, based on its use in other related trials,35 a Mini-
Mental State Examination (MMSE)36,37 was also performed.
Neuropsychological Evaluation
A neuropsychologist or psychometrician at each participating
IHAST center was certified by a review of credentials, with
the requirement of documented training at a reputable neu-
ropsychological training program and at least 1 year of expe-
rience administering neuropsychological tests. Standardized
test materials and instructions were provided to each center.
Examiners were unaware of group assignment. If a patient
could not be examined at the operating center, arrangements
were made for them to be evaluated by trained examiners at
another location. Patient age, years of education, and hand-
edness were also recorded. All raw data were sent to the Uni-
versity of Iowa for scoring by a single technician (K.W.M.)
who was also unaware of treatment group. Test performances
were compared with appropriate age- and education-adjusted
normative data31–34 (J. S. Wefel and K. E. Boward. Norma-
tive data for the Complex Figure Test. Unpublished data.
Department of Neurology, University of Iowa, Iowa City,
IA, 1995). The following results were converted to T-scores:
Benton Visual Retention Test number correct, COWA,
Rey–Osterrieth Complex Figure–Copy, GPB right hand
time to completion, GPB left hand time to completion, and
Trail Making Test B. Individual T-scores were then averaged
to provide a Composite Score, which provided an index of
global cognitive status.
If all of the tests were not completed, a Composite Score
was calculated based on those tests that were completed, pro-
vided at least three scores were available. If fewer than three
of the tests were completed, a Composite Score was not cal-
culated, but patients were classified as being globally im-
paired or not impaired by a process of imputation (see later),
based on the results of their other neurological assessments.
Impairment on either an individual test or on the Com-
posite Score was defined as a T-score of 30 or less, which is
2 SDs below the population norms. Impairment on the
MMSE was also defined as a score two or more SDs below
the age- and education-adjusted norm.37
MISSING DATA/IMPUTATION OF IMPAIRMENT. Neuropsy-
chological testing (excluding the MMSE) was not completed
in 66 (7%) surviving patients, 31 in the hypothermic group
and 35 in the normothermic group. In 54 of these patients,
no neuropsychological testing was performed, whereas 10 pa-
tients completed a single test (most commonly the COWA)
and 2 patients completed two tests. However, on inspection,
it was apparent that the characteristics of the untested pa-
tients differed substantially between the two treatment
groups. For example, of the 31 hypothermic patients without
Composite Scores, 18 (58%) were classified as “medically
untestable” by the examiner, and 21 (68%) had GOSs of 3
or 4 (severe impairment or vegetative state, respectively). In
contrast, only 12 normothermic patients (34%) were consid-
ered to be medically untestable or had GOSs of 3 or 4.
Patients without Composite Scores were distributed
equally across all participating centers and across the dura-
tion of the study; no evident “pattern” suggesting bias could
be identified. Nevertheless, neuropsychological impairment is
more likely in patients with severe neurological disability. Be-
cause excluding more “poor outcome” patients from one
group has the potential to “bias” the results in favor of that
group, it was necessary develop a process by which patients
without Composite Scores could be included in the outcome
assessment process.
To eliminate the possibility of arbitrary assignment and
subjective bias, we developed a computerized imputation
process to relate our four principal outcome measures (GOS,
Rankin Disability Scale, NIHSS, and Barthel ADL) to neu-
ropsychological outcomes; at least two of these test results
were available for all patients. The imputation process used
data from the 873 patients who did have Composite Scores.
We used logistic regression to relate our four neurological
outcome measures to the presence or absence of neuropsy-
chological impairment on the Composite Score. Because at
least 2 of these neurological outcome measures were available
for each of the 66 individuals without Composite Scores, it
was possible to determine the likelihood that any given pa-
tient would have been classified as impaired, compared with
the group of patients with Composite Scores. For example, a
patient with GOS  3, Rankin Disability Scale score  4,
NIHSS  18, and Barthel ADL  20 had a 99.99% like-
lihood of being impaired, whereas an individual with
GOS  1, Rankin Disability Scale score  1, NIHSS  0,
and Barthel ADL  100 had only an 11% chance of being
impaired.
This algorithm was then applied to the 66 patients with
missing Composite Scores. Patients with a calculated likeli-
hood of impairment of 80% or more were classified as “im-
paired.” This cutoff was selected to ensure that only patients
with a high likelihood of impairment were so classified; the
imputation algorithm, when tested on patients with mea-
sured Composite Scores, had a high specificity (99.3%), a
relatively low sensitivity (approximately 20.6%), and high
positive and negative predictive value (86.8 and 84.8%, re-
spectively). As such, it intentionally underestimates the actual
number of impaired patients among individuals with missing
Composite Scores.
Note that this process was used only to impute the likeli-
hood of impairment on the Composite Score; no effort was
made to impute values for actual numerical Composite
Scores or impairment on individual test results.
Data Analysis
All data entry and analyses were performed by the Data
Management Center at the University of Iowa.
The impact of treatment (hypothermia vs normothermia)
on neuropsychological outcome was assessed using three
principal measures. First, the distribution of outcomes based
on Composite Score (unimpaired, impaired, and dead) were
compared using the Cochran–Mantel–Henzel general associ-
ation test, adjusting for center, stratum, and treatment.38 As
noted earlier, a patient was considered to be “impaired” if his
or her Composite Score was 30 or less (2 or more SDs below
the norm) or, in the event that a Composite Score was not
available, based on the previously noted imputation process.
Second, the distribution of outcomes based on whether a
patient was impaired on one or more neuropsychological tests
was compared using a similar process. A patient with impair-
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ment on any single test would be considered as “impaired on
one or more tests” regardless of results on any other tests (or
the absence of any other test results). If no test results were
available, and the imputation process noted above classified
the patient as “impaired” on the Composite Score, they were
also considered to be “impaired on one or more test.” If they
were classified as “unimpaired” by imputation, they were also
classified as “unimpaired” on one or more tests.
Third, the results for individual tests (T-scores) and com-
posite scores were expressed as mean  SD. No effort was
made to impute individual or Composite Scores, and because
of imbalances in characteristics of missing patients, no
between-groups statistical comparisons were performed. To
explore the relative sensitivities of the different tests, we per-
formed within-group comparisons of individual T-scores and
the incidence of impairment on individual tests using analy-
sis of variance.
Finally, we performed the identical evaluations on the
subpopulation of patients with WFNS score of I at the time
of enrollment. We focused on this subpopulation because
these patients have the least amount of posthemorrhage
physiological and functional disturbance. As such, they have
the “most to lose” for a result of events during surgery (hy-
potension, brain retraction, temporary vessel occlusion) or af-
terward (eg, vasospasm). If intraoperative hypothermia were
to confer neurological protection and preserve remaining
neurological and/or neuropsychological function, the treat-
ment effect might be most obvious in the WFNS I popula-
tion.
Results
Between February 2000 and April 2003, 3,966 patients
underwent intracranial aneurysm surgery at 30 partici-
pating centers. Of this group, 2,856 had suffered an
acute SAH. A total of 1,183 of these patients were el-
igible, and 1,033 were enrolled. Due to changes in sta-
tus after enrollment, 32 enrolled patients were not ran-
domized, resulting in a total of 1,001 subjects. Three-
month GOS scores were obtained in 1,000 patients
(499 hypothermia and 501 normothermia). Sixty-one
patients died (29 in the hypothermic group and 32 in
the normothermic group). Among the surviving pa-
tients, Rankin Disability Scale scores were available for
all 939, Barthel ADLs were available for 938, and
NIHSS scores were available for 913. At least 1 neu-
ropsychological test was completed by 885 patients,
and a Composite Score was available for 873 (93% of
survivors; 439 in the hypothermic group and 434 in
the normothermic group). MMSEs were completed in
883 patients (448 hypothermia and 435 normother-
mia).
Baseline characteristics of the efficacy population, as
well as nonneuropsychological outcomes, can be found
in our previous publication.13 In the hypothermic and
normothermic groups, 65 and 66% of patients were
female, mean (SD) ages were 52  12 and 51  13
years, and average years of education were 11.6  2.9
and 11.7  2.7 years, respectively. The frequencies of
premorbid neurological disease, psychiatric disease, and
alcohol abuse did not differ between groups (Table 1).
Other than the planned differences in intraoperative
temperatures (33.2  0.9°C vs 36.5  0.7°C, mean 
SD), significant intergroup differences were noted for
blood glucose at the time of first clip application (hy-
pothermia vs normothermia: 138  37 vs 127 
31mg/dl), total operative crystalloid administration
(hypothermia vs normothermia: 3.8  1.6 vs 3.3
1.5L), and urine output (hypothermia vs normother-
mia: 2.1 1.3 vs 1.7  1.6L). A total of 25.1% of
hypothermic patients remained intubated at 2 hours af-
ter surgery versus 13.2% of normothermic patients.
There were no intergroup differences in GOS, Rankin
Disability Scale score, Barthel ADL, or NIHSS; 66%
of hypothermic group patients had a GOS  1, versus
63% of normothermic group patients (p  0.32; odds
ratio, 1.14 [95% confidence interval, 0.88–1.48]).
Neuropsychological Outcomes
IMPAIRMENT ON COMPOSITE SCORE. As noted, 873 of
the 939 surviving patients completed 3 or more indi-
vidual tests and could be directly classified as “im-
paired” or “unimpaired” from their Composite Scores
(Table 2). Impairment status was imputed in the re-
maining 66 based on the process described earlier. In
the hypothermic group, 16.8% of patients were classi-
fied as “impaired” (17.9% of surviving patients) com-
pared with 20.0% in the normothermic group (21.3%









Neurological disease 46 (10.5%) 29 (6.7%) 75 (8.6%) 0.053
Psychiatric disease 7 (1.6) 6 (1.4%) 13 (1.5%) 1.00
Alcohol abuse 34 (7.7%) 33 (7.6%) 67 (7.7%) 1.00
These data represent those subjects who completed sufficient testing to generate a Composite Score. Neurological disease includes prior history
of stroke, tumor, head trauma, epilepsy, or other major neurological disease. There were no significant differences between treatment groups
based on Fisher’s exact test.
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of surviving patients). There were no intergroup dif-
ferences in the distribution of outcomes ( p  0.317).
The relationship between outcome as assessed by
GOS and neuropsychological impairment is shown in
Table 3.
IMPAIRMENT ON ONE OR MORE INDIVIDUAL TESTS.
Approximately 50% of patients in both groups were
classified as being “impaired” on one or more individ-
ual neuropsychological tests (Table 4). There were no
differences in the distribution of outcomes (p 
0.865).
INDIVIDUAL TEST RESULTS. The frequencies of impair-
ment in each cognitive domain assessed, for the two
treatment groups combined, are presented in Table 5.
The results for individual tests within each treatment
group are shown in Table 6. The Composite Score
(based only on tested patients) was 41.0  10.0
(mean  SD) in the hypothermic group versus 38.7 
10.8 in the normothermic group. Mean T-scores on
individual tests ranged from 35.5  13.3 (GPB-Left,
normothermia) to 45.2  11.8 (COWA, hypother-
mia). The fraction of patients with impairment on a
given test ranged from a low of 9% (COWA, hypo-
thermia) to 38% (GPB-Left, normothermia).
MINI-MENTAL STATE EXAMINATION. In the hypother-
mic group, 448 of the 470 surviving patients com-
pleted the MMSE, compared with 435 of the 469 nor-
mothermic patients. Mean (SD) scores for those
completing the test were 27.4  3.8 in the hypother-
mic group versus 26.8  4.5 in the normothermic
group. Of the tested survivors in the hypothermic
group, 14.5% were classified as impaired versus 18.4%
in the normothermic group. However, as for patients
with missing Composite Scores, the distribution of
outcomes in patients not completing the MMSE dif-
fered between the two treatment groups. Of the 22 hy-
pothermic patients without MMSEs, 4 (18%) had
GOSs  1. By contrast, of the 34 normothermic pa-
tients without MMSEs, 20 (59%) had GOSs  1. As
a result, no direct statistical comparison of the two
treatment groups was performed. An imputation algo-
rithm was applied to the 56 patients with missing
MMSEs, similar to that developed for the Composite
Score. Patients with a calculated likelihood of impair-
ment of 80% or more were classified as “impaired” on
the MMSE. In the combined group of subjects with
MMSE scores and imputed impairment status, there
were no intergroup differences in the distribution of
outcomes (p  0.386).
WFNS  I SUBPOPULATION. Analyses similar to those
above were performed on the 660 patients (332 hypo-
thermic and 328 normothermic patients) with the least
degree of initial impairment; that is, those with an ad-
mission WFNS scores of I. The results were similar to
the entire study population. In the hypothermic group,
13.3% of patients were classified as “impaired” on the
Composite Score versus 18.3% of normothermic group
patients (p  0.099). Likewise, impairment on one or
more tests was equivalent between treatment groups
(hypothermia: 53.6%; normothermia 52.7%; p 
0.970).
Discussion
The IHAST study tested the hypothesis that mild in-
traoperative hypothermia would increase the incidence
of “good outcomes” in patients undergoing surgical
therapy (clipping) for aneurysmal SAH as assessed by
the GOS at 3 months after surgery. As reported previ-
ously, no treatment effects were detected despite a suf-
ficiently large trial, high protocol compliance, and ex-
cellent follow-up. In addition, no differences were seen
in several secondary measures of neurological function,








Unimpaired, n 375 11 386 (77.4%) 345 24 369 (73.7%)
Impaired, n 64 20 84 (16.8%) 89 11 100 (20.0%)
Dead, n 29 (5.8%) 32 (6.4%)
Total, n 439 31 499 434 35 501
The Composite Score is the average of the individual T-scores for the six administered tests.
aThere was no significant different in the distribution of outcomes between hypothermia and normothermic groups (CMH general association
test, p  0.317).
bPatients completed 3 or more tests; impairment indicates a score that is 2 or more standard deviations below the norm (T-score  30).
cPatients did not complete neuropsychological testing, and their impairment status was determined using a logistic regression imputation
process based on their recorded Glasgow Outcome Scale, Rankin Disability Scale, Barthel’s Activities of Daily Living index, and National
Institutes of Health Stroke Scale scores.
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including the Rankin Disability Scale, the NIHSS, and
the Barthel ADL. We can hence conclude that intra-
operative cooling does not improve functional and/or
neurological outcome in this group of patients.
The GOS was chosen as our primary outcome as-
sessment instrument for IHAST based on its prior use
in many SAH-related trials15,39–44 We chose the
Rankin Disability Scale as a secondary outcome for
largely the same reasons, that is, its widespread use and
its demonstrated ability to respond to treatment inter-
ventions.45 However, both scores are relatively crude,
focusing on general functionality rather than on dis-
crete neurological and/or cognitive abnormalities. They
may not be sensitive to small but possibly important
differences between groups. Another secondary assess-
ment, the NIHSS,30 provides considerably more neu-
rological detail but is heavily weighted toward focal
motor abnormalities. It was designed to evaluate pa-
tients with occlusive stroke, and recent work suggests
that it has limitations as an outcome measure in
SAH.46 As a result, we were concerned from the outset
that our neurological outcome measures might not be













1 303 19 0 7 329 262 34 0 18 314 643
2 70 32 1 2 105 73 30 0 5 108 213
3 2 13 18 2 35 10 25 11 1 47 82
4 0 0 1 0 1 0 0 0 0 0 1
5 29 32 61
Total 499 501
The relationship between Glasgow Outcome Scale (GOS) and Neuropsychological Impairment on the Composite Score. The columns labeled
as “untested” are divided into impaired or unimpaired according to the imputation algorithm described in Subjects and Methods.







Unimpaired 188 9 197 (39.5%) 166 24 190 (37.9%)
Impaired 258 15 273 (54.7%) 268 9 279 (55.7%)
Dead 29 (5.8%) 32 (6.4%)
Total 446 24 499 436 33 501
aThere were no significant differences in the distribution of outcomes between hypothermia and normothermic groups (CMH General Asso-
ciation Test, p  0.865).
bA “tested” patient was classified as impaired on one or more individual tests if the T-score for any test was two or more standard deviations
below the norm, regardless of the actual number of tests completed.
cAn “untested” patient was classified as impaired only if they had failed to take any tests and if their imputed Composite Score was impaired.
Table 5. Cognitive Functions Affected
Function Test Tested, n
Fraction
Impaired Untested, n
Short-term memory BVRT 869 27% 70
Cued word finding COWA 868 12% 71
Visuospatial/constructional ability CFT 864 28% 75
Visuomotor coordination (RH) GPB Rt 852 32% 87
Visuomotor coordination (LH) GPB Lt 838 33% 101
Executive function TMT-B 852 18% 87
Impairments were common across all cognitive domains assessed. Most frequently affected were visuomotor coordination (assessed with a timed
unimanual pegboard task), visuospatial/constructional ability (assessed through paper and pencil copy of a complex geometric figure), and
short-term memory (assessed with the immediate reproduction of a series of increasingly complex geometric figures, after brief visual exposure).
BVRT  Benton Visual Retention Test; COWA  Controlled Oral Word Association; CFT  Complex Figure Test; RH  right hand;
GPB  Grooved Pegboard; LH  left hand; TMT-B  Trail Making Test Part B.
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able to detect subtle and yet nevertheless important
treatment effects.
We did not choose a neuropsychological outcome as
our primary outcome for several reasons. First, neuro-
psychological testing has not previously been used as a
primary outcome measure in SAH. There is no widely
accepted “standard” battery of neuropsychological tests
for use in this situation. In fact, even the definition of
“impairment” on such tests after SAH has not been
well defined. Nevertheless, we had reason to believe
that neuropsychological testing might be more sensitive
to SAH-related injury, and hence treatment. There
have been many published studies demonstrating a
high incidence of neurocognitive deficits among survi-
vors of SAH, even those with good functional out-
comes. For example, Hutter and colleagues20 demon-
strated that 28% to 62% of “Good Outcome” (by
GOS) patients studied 6 months after their SAH dem-
onstrated abnormalities on one or more neuropsycho-
logical tests. Others have also demonstrated a high in-
cidence of cognitive abnormalities after SAH.5,7,21–25
In addition, neuropsychological testing has been shown
to reflect treatment effects for other disorders.16–19 For
this reason, we included a brief battery of neuropsycho-
logical tests.
Our first challenge was to develop a battery of tests
that could be administered easily on a large multi-
center/multinational scale. Standard neuropsychological
testing is often a long and time-consuming procedure,
and many tests are language dependent. We believed
that to be feasible in a large multicenter trial such as
this one, a shorter and more easily administered test
battery was essential. It was also important to select a
series of tests that covered the major cognitive domains
and that were known to be frequently affected in pa-
tients recovering from SAH. This selection process was
accomplished by using the Patient Registry of the Di-
vision of Cognitive Neuroscience, in the Department
of Neurology at the University of Iowa. Based on a
review of data from patients with SAH, we selected five
well-known and widely used tests whose results corre-
lated well with results of a more comprehensive test
battery. We also included the MMSE largely because
of its widespread use as an outcome measure in rele-
vant studies.35,46 The tests were administered in each
center by trained neuropsychologists or neuropsychol-
ogy technicians whose qualifications were all reviewed
by the Iowa Steering Committee. We intentionally
chose a relatively “conservative” definition of “impair-
ment,” that is, a T-score of two or more SD below the
age-, sex-, and education-adjusted norm.
The findings from this study provide support for the
feasibility of incorporating neuropsychological testing
into the outcome measures for clinical trials in which
changes in cognitive function might be expected. How-
ever, it also highlights the limitations of such testing in
trials where a substantial number of patients might be
expected to have severe brain damage. We had no dif-
ficulty recruiting trained neuropsychologists and neu-
ropsychology technicians at our participating centers,
all of which were major medical centers with neurosur-
gical units. No potential center was excluded because
neuropsychology support was not available. The bat-
tery of tests proved to be readily performed with 93%
of surviving patients completing testing. This repre-
sents the largest prospective assessment of neuropsy-
chological abnormalities after SAH currently published.
However, there were problems. In any clinical trial, the











BVRT 436 42.3  14.1 23% 34 433 38.5  15.0 31% 36
COWA 434 45.2  11.8 9% 36 434 43.5  12.3 15% 35
CFT 437 39.9  18.5 27% 33 427 38.3  19.0 29% 42
GPB Rt 427 37.6  13.2 30% 43 425 35.6  13.9 33% 44
GPB Lt 419 37.1  12.7 28% 51 419 35.3  13.3 38% 50
TMT-B 424 43.7  12.5 13% 46 428 41.6  13.3 22% 41
Composite 439 41.0  10.0 15% 31 434 38.7  10.8 21% 35
Because of the different characteristics of “untested” patients in the hypothermic and normothermic groups, no statistical comparisons were
performed on individual test scores or on the numeric Composite Score.
a“Tested” indicates the number of patients who completed a given test.
bThe T-score (mean  standard deviation [SD]) is based on comparing the patient’s age-, sex-, and education-adjusted raw scores with
published norms.
cThe “fraction impaired” indicates the percentage of patients whose T-score was 30 (which is 2 SD below the norm).
BVRT  Benton Visual Retention Test; COWA  Controlled Oral Word Association; CFT  Complex Figure Test; GPB Rt and Lf 
Grooved Pegboard, right and left hand; TMT-B  Trail Making Test Part B; Composite  Composite Score, which is the average of all
individual T-scores for a patient.
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utility of an outcome measure is dependent on the suc-
cess with which it can be applied to the largest possible
fraction of treated patients. Failure to test a significant
proportion of randomized patients can introduce bias if
the characteristics of those untested patients differ be-
tween treatment groups or are dissimilar from the over-
all study group. This was not a problem for our pri-
mary outcome measure (GOS); only 1 patient was lost
of a total of 1,001 randomized patients. However,
roughly 7% of our surviving patients did not undergo
complete neuropsychological testing, and it is clear that
this untested group was differed from the overall effi-
cacy population. In the overall trial, 69% of the 939
surviving patients were classified as GOS  1, 23% as
GOS  2 (moderate disability), and 9% as GOS  3
(severe disability). By contrast, of the 66 patients with
missing Composite Scores, 39% were classified as
GOS  1 and 48% were GOS  3. Of those patients
missing a Composite Score, 45% (30/66) were classi-
fied as “medically untestable,” indicting that neuropsy-
chological testing of the sort used in this trial is not
readily completed by severely injured patients, even
when other outcome measures (GOS, NIHSS) can be
assigned.
Use of this form of neuropsychological testing as a
primary outcome measure in clinical trials that involve
a significant number of severely brain damaged patients
could result in a relatively high rate of loss to follow-
up. One approach to this problem would be to incor-
porate simpler cognitive behavioral tests that might be
completed by more patients (eg, questions regarding
orientation to time and place, repeating digits, simple
yes/no questions). However, in this study, the number
of patients who completed the MMSE, which uses
such simple items, was nearly identical to the number
completing at least one neuropsychological test. Fur-
thermore, the MMSE was less sensitive to cognitive
deficits than was the neuropsychological testing; of the
151 patients with impaired Composite Scores who also
completed the MMSE, only 88 (58%) were found to
be impaired on the MMSE.
It is unclear whether testing of cognitive function
adds to our assessment of patients with severe damage.
A better approach might be to restrict neuropsycholog-
ical testing a priori to predefined “eligible patients”
with otherwise good outcomes according to neurolog-
ical rating scales. This would preclude the use of neu-
ropsychological testing as a primary outcome measure
for many trials, but would take advantage of the
unique information provided by neuropsychology as a
secondary outcome measure. If we used this approach
with our own data, 5.8% of hypothermic GOS  1
patients were cognitively impaired (by Composite
Score) versus 10.8% of normothermic patients; 49.2%
and 49.7% of hypothermic and normothermic GOS 
1 patients were impaired on at least one test.
Of even greater importance to this study was that
the distribution of neurological outcomes in patients
with missing Composite Scores differed significantly
between the two treatment groups (see Table 4). We
were unable to identify any cause of this maldistribu-
tion and concluded that this was a consequence of the
randomization process. This maldistribution problem
made it critical that, if we wished to use the Composite
Score as a global measure of neuropsychological out-
come, some method be used to estimate the likelihood
of impairment in patients with missing Composite
Scores; without doing so, our results would be incon-
sistent with the primary outcome. That is, if we ana-
lyze only those patients with Composite Scores, we
would conclude that hypothermia resulted in a signif-
icantly greater fraction of GOS  1 patients than nor-
mothermia, a finding that conflicts with our primary
result.13 Similarly, we would conclude that neuropsy-
chological outcomes were better in hypothermic group
patients. However, we believe that this conclusion
would be incorrect and misleading, because it would be
due solely to the imbalance in the follow-up procedure,
and not to a direct treatment effect. For this reason, we
developed a logistic, regression-based imputation pro-
cess. Although one might argue with the cut point for
designation of “impairment” on the Composite Score
(80% likelihood of impairment), this approach
avoided introducing investigator bias or subjectivity
into the determination of “impairment” in patients
with missing Composite scores. However, we did not
consider the imputation process to be sufficiently reli-
able as to impute more specific data such as: (1) actual
Composite Score values in untested patients, or (2) es-
timate scores for missing individual neurocognitive
tests. Thus, because of missing individual scores and
the unreliability of imputed individual scores, our abil-
ity to reliably compare the effect of intraoperative hy-
pothermia on individual neurocognitive test scores was
restricted.
Despite these limitations, the neuropsychological
battery proved to be sensitive to cognitive deficits that
were not apparent by the use of global outcome mea-
sures. Although the incidence of impairment on our
Composite Score was lower than the incidence of less-
than-good outcomes on the GOS (18.4% impairment
vs 35.7% for GOS values of 1), a large fraction of
GOS  1 patients had some neurocognitive impair-
ment. For example, of the 643 patients categorized as
“good outcome” (GOS  1), 53 (8.2%) were classified
as “impaired” on Composite Score, and 318 (49.5%)
were “impaired” on at least 1 test. These results are
generally consistent with the results of others who have
studied SAH.
One contemporary question of interest to clinicians
involves the relative importance of SAH itself versus
treatment on outcome. Are long-term deficits (neuro-
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logical and neuropsychological) due to the SAH itself,
or are they modified by treatment? Recent studies sug-
gest a modestly lower morbidity and mortality among
patients treated with coiling versus surgery, but it is
also impossible to study untreated patients with SAH.
The IHAST study was not designed to address this is-
sue, but some insight may be gained by examining out-
come in patients with differing “baseline” neurological
conditions, that is, those with prerandomization
WFNS values of 1 versus poorer outcomes. Theoreti-
cally, “surgical” injury would be more evident in pa-
tients with the least degree of presurgical dysfunction
(and who would be predicted to have the best out-
comes). Among our 660 WFNS  I patients, 473
(71.7%) were classified as having a “good outcome”
(GOS  1), 25 patients died (3.8%), and 103 (15.6%)
were “impaired” on their Composite Score. Conversely,
of the 340 patients with baseline WFNS  2 or 3, 170
(50%) had good outcomes, 36 (10.6%) died, and 88
(20.5%) were impaired. These differences are statisti-
cally significant and support the idea that a major frac-
tion of a patient’s outcome is defined by the underly-
ing severity of their SAH.
In summary, our results do not support the hypoth-
esis that intraoperative hypothermia improves neuro-
cognitive outcome in good-grade SAH patients under-
going surgery for the treatment of ruptured intracranial
aneurysms. They do, however, demonstrate that neu-
ropsychological testing is a feasible outcome measure.
Like other investigators, our results suggest that there is
a high incidence of neuropsychological deficits in this
population, even among patients considered to have
otherwise good outcomes. This result, combined with
the problems we encountered with follow-up (particu-
larly in poor-grade patients), suggests that neuropsy-
chological testing may best be used to refine our out-
come assessments in good-grade patients rather than as
a “global” assessment of outcome.
This work is supported by the NIH (National Institute of Neuro-
logical Disease and Stroke, RO1 NS38554, M.M.T.).
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